Abstract: An intracorporeal marker delivery system includes a delivery device including a delivery cannula and a plunger. The delivery cannula has an inner lumen, a distal tip, and a discharge opening in communication with the inner lumen. A radiographically detectable marker having a fibrous-body and a radiographically detectable marker element coupled to the fibrous body is disposed within and pushable by the plunger through the inner lumen of the delivery cannula. An MRI detectable distal tip plug is disposed at least in part within a distal portion of the inner lumen distal to the radiographically detectable marker, and configured to partially occlude the discharge opening in the delivery cannula. An ultrasound detectable short term marker is interposed between the radiographically detectable marker and the MRI detectable distal tip plug in the inner lumen of the delivery cannula.

Abstract: A merchandiser that includes a case defining a product display area and a base defining a compartment below the product display area. The merchandiser includes a shelf coupled to the case within the product display area adjacent the base. The shelf is disposed over the compartment and includes a first portion and a second portion. Each of the first portion and the second portion define a product support area to support food product. Also, the second portion is pivotable relative to the first portion to provide access to the compartment.

Abstract: An automated system and method of cryopreservation of oocytes, embryos, or blastocysts. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

Abstract: A mass includes particles that exhibit an in vivo lifetime and that include a bioresorbable material and bubble cavities disposed in the particles, wherein the bubble cavities have length, width, and height dimensions at least one of which is less than or equal to about 2000 microns. The mass exhibits enhanced detectability by ultrasound energy during the lifetime; the lifetime begins upon exposure to in vivo fluids and ends between about 2 and about 20 weeks afterward; and a zero or non-zero fluid-to-solid ratio.

Abstract: An automated system and method of preparing oocytes, embryos, or blastocysts for cryopreservation. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

Abstract: The disclosure describes devices and methods for asymmetrical irradiation at a body cavity or site, such as after removal of tissue, e.g. biopsy or cancer. One device includes a lumen which is off-set or off-settable from a longitudinal axis to increase the intensity of radiation received from a radiation source by a first tissue portion surrounding the body cavity and to reduce or minimize radiation received by a second tissue portion (e.g. healthy tissue) surrounding the body cavity.

Abstract: An automated system and method of preparing oocytes, embryos, or blastocysts for cryopreservation. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

Abstract: An automated system and method of preparing oocytes, embryos, or blastocysts for cryopreservation. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

Abstract: An automated system and method of cryopreservation of oocytes, embryos, or blastocysts. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

Abstract: An automated system and method of cryopreservation of oocytes, embryos, or blastocysts. The method entails delivering two or more solutions into a container holding oocytes, embryos, or blastocysts, and controlling the flow of the solutions to gradually change the concentration of cryoprotectants and dehydrating agents in the container to minimize shock to the oocytes, embryos or blastocysts.

Abstract: The disclosure describes devices and methods for asymmetrical irradiation at a body cavity or site, such as after removal of tissue, e.g. biopsy or cancer. One device includes a lumen which is off-set or off-settable from a longitudinal axis to increase the intensity of radiation received from a radiation source by a first tissue portion surrounding the body cavity and to reduce or minimize radiation received by a second tissue portion (e.g. healthy tissue) surrounding the body cavity.

Abstract: The invention relates to heterocyclic compounds and their use as antibiotics and/or as antibiotic potentiators. The compounds may act as colistin potentiators and SOS inhibitors.

Abstract: A biopsy site marker having at least one small marker body or pellet of bioresorbable material such as gelatin, collagen, polylactic acid, polyglycolic acid which has a radiopaque object, preferably with a non-biological configuration. The at least one bioresorbable body or pellet with a radiopaque object is deposited into the biopsy site, by a delivery device that includes an elongated tubular body with a piston slidable within the tubular body. One end of the tube is placed into the biopsy site. At least one but preferably several marker bodies or pellets are deposited sequentially into the biopsy site through the tube. At least the bioresorbable materials of the detectable markers remain present in sufficient quantity to permit detection and location of the biopsy site at a first time point (e.g., 2 weeks) after introduction but clear from the biopsy site or otherwise do not interfere with imaging of tissues adjacent the biopsy site at a second time point (e.g., 5-7 months) after introduction.

Abstract: A mass includes particles that exhibit an in vivo lifetime and that include a bioresorbable material and bubble cavities disposed in the particles, wherein the bubble cavities have length, width, and height dimensions at least one of which is less than or equal to about 2000 microns. The mass exhibits enhanced detectability by ultrasound energy during the lifetime; the lifetime begins upon exposure to in vivo fluids and ends between about 2 and about 20 weeks afterward; and a zero or non-zero fluid-to-solid ratio.

Abstract: The bioabsorbable implant described has a porous body formed of bioabsorbable materials that have an in vivo life span of at least 2 weeks, preferably at least three weeks and not greater than 20 weeks, preferably no greater than ten weeks. The implant has a scaffolding structure which facilitates tissue in-growth and ultimately tissue replacement of the scaffolding structure. The implant has a radiopaque imaging agent at least at the exterior margins and an orientation plurality of radiopaque elements in the interior of implant. The implant preferably has three radiopaque elements within the interior that form a plane within the implant interior.

Abstract: An endoluminal needle or punch is describes wherein the distal end of the endoluminal needle is able to articulate laterally out of the longitudinal axis of the steerable endoluminal needle. The endoluminal needle further comprise a blunted distal end configuration that is minimally traumatic. Under control by the user, at the proximal end of the endoluminal needle, a sharp stylet can be advanced to punch tissue and then be retracted to maximize safety. The endoluminal needle is configured for use within an introducer.

Abstract: A medical device includes a shaft having a distal end and a distal tip. An anchor mechanism is coupled to the distal end proximal to the distal tip. The anchor mechanism includes a rolled sheet of material and a sleeve located to surround the rolled sheet of material to maintain the rolled sheet of material in an initial rolled configuration, and is configured such that when the sleeve is retracted, the rolled sheet of material unrolls to expand radially to anchor the medical device.

Abstract: A device and method for treating restless leg syndrome by transmitting sound proximate the leg or legs of a patient with sound in the range of 20 to 100 Hertz, or 20 to 100 beats per second. The method may be accomplished using sound generators disposed within a pad or sleeve.

Abstract: A method for treating a site within a patient from which tissue has been removed includes providing at least one press-formed marker body formed of polysaccharide and a suitable binder; and placing the at least one of the press-formed marker body within the site where tissue has been removed so as to provide hemostasis therein.

Abstract: A method of marking a biopsy site within a patient's body includes providing a delivery tube having a plunger; carrying a quantity of an ultrasound-detectable bio-resorbable particulate material in the delivery tube distal to the plunger, the ultrasound-detectable bio-resorbable particulate material having a particle size between about 200 microns and about 500 microns and having internal bubble cavities having a size of at least 50 microns; and depressing the plunger for depositing the quantity of the ultrasound-detectable bio-resorbable particulate material at the biopsy site.